Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis

Md Mohaimenul Islam, Tahmina N Poly, Bruno A Walther, Navneet K Dubey, Dina N Anggraini Ningrum, Syed-Abdul Shabbir, Yu-Chuan Jack Li

研究成果: 雜誌貢獻回顧型文獻

10 引文 (Scopus)

摘要

The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare professionals and patients about their potentially adverse effects. In July 2016, we searched through Medline (PubMed), Embase, and the Cochrane Library from inception using common keywords. We included observational studies that provided risk estimates on the long-term use of PPIs and their adverse effects. Overall, 43 studies were included in the systematic review, of which 28 studies were also included in the random effect meta-analysis. Odds of community-acquired pneumonia, hip fracture, and colorectal cancer were 67% [odds ratio (OR)=1.67; 95% confidence interval (CI): 1.04-2.67], 42% (OR=1.42; 95% CI: 1.33-1.53), and 55% (OR=1.55; 95% CI: 0.88-2.73) higher in patients with long-term PPIs use compared with patients who did not use PPIs. Although the use of PPIs provides short-term health benefits, their prolonged use is associated with minor and also potentially major adverse health outcomes. Hence, we strongly recommend that the prescription of PPIs should be done with caution to improve the medication's efficacy and patients' safety.

原文英語
頁(從 - 到)1395-1405
頁數11
期刊European Journal of Gastroenterology and Hepatology
30
發行號12
早期上線日期七月 19 2018
DOIs
出版狀態已發佈 - 十二月 1 2018

指紋

Proton Pump Inhibitors
Meta-Analysis
Odds Ratio
Confidence Intervals
Hip Fractures
Insurance Benefits
Patient Safety
PubMed
Libraries
Observational Studies
Prescriptions
Colorectal Neoplasms
Pneumonia
Delivery of Health Care
Health

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

引用此文

Adverse outcomes of long-term use of proton pump inhibitors : a systematic review and meta-analysis. / Islam, Md Mohaimenul; Poly, Tahmina N; Walther, Bruno A; Dubey, Navneet K; Anggraini Ningrum, Dina N; Shabbir, Syed-Abdul; Jack Li, Yu-Chuan.

於: European Journal of Gastroenterology and Hepatology, 卷 30, 編號 12, 01.12.2018, p. 1395-1405.

研究成果: 雜誌貢獻回顧型文獻

Islam, Md Mohaimenul ; Poly, Tahmina N ; Walther, Bruno A ; Dubey, Navneet K ; Anggraini Ningrum, Dina N ; Shabbir, Syed-Abdul ; Jack Li, Yu-Chuan. / Adverse outcomes of long-term use of proton pump inhibitors : a systematic review and meta-analysis. 於: European Journal of Gastroenterology and Hepatology. 2018 ; 卷 30, 編號 12. 頁 1395-1405.
@article{3f503cf6490c494da741fb31613494bf,
title = "Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis",
abstract = "The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare professionals and patients about their potentially adverse effects. In July 2016, we searched through Medline (PubMed), Embase, and the Cochrane Library from inception using common keywords. We included observational studies that provided risk estimates on the long-term use of PPIs and their adverse effects. Overall, 43 studies were included in the systematic review, of which 28 studies were also included in the random effect meta-analysis. Odds of community-acquired pneumonia, hip fracture, and colorectal cancer were 67{\%} [odds ratio (OR)=1.67; 95{\%} confidence interval (CI): 1.04-2.67], 42{\%} (OR=1.42; 95{\%} CI: 1.33-1.53), and 55{\%} (OR=1.55; 95{\%} CI: 0.88-2.73) higher in patients with long-term PPIs use compared with patients who did not use PPIs. Although the use of PPIs provides short-term health benefits, their prolonged use is associated with minor and also potentially major adverse health outcomes. Hence, we strongly recommend that the prescription of PPIs should be done with caution to improve the medication's efficacy and patients' safety.",
keywords = "Alzheimer, cancer, cardiac disease, gastroesophageal reflux disease, kidney disease, proton pump inhibitors",
author = "Islam, {Md Mohaimenul} and Poly, {Tahmina N} and Walther, {Bruno A} and Dubey, {Navneet K} and {Anggraini Ningrum}, {Dina N} and Syed-Abdul Shabbir and {Jack Li}, Yu-Chuan",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/MEG.0000000000001198",
language = "English",
volume = "30",
pages = "1395--1405",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Adverse outcomes of long-term use of proton pump inhibitors

T2 - a systematic review and meta-analysis

AU - Islam, Md Mohaimenul

AU - Poly, Tahmina N

AU - Walther, Bruno A

AU - Dubey, Navneet K

AU - Anggraini Ningrum, Dina N

AU - Shabbir, Syed-Abdul

AU - Jack Li, Yu-Chuan

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare professionals and patients about their potentially adverse effects. In July 2016, we searched through Medline (PubMed), Embase, and the Cochrane Library from inception using common keywords. We included observational studies that provided risk estimates on the long-term use of PPIs and their adverse effects. Overall, 43 studies were included in the systematic review, of which 28 studies were also included in the random effect meta-analysis. Odds of community-acquired pneumonia, hip fracture, and colorectal cancer were 67% [odds ratio (OR)=1.67; 95% confidence interval (CI): 1.04-2.67], 42% (OR=1.42; 95% CI: 1.33-1.53), and 55% (OR=1.55; 95% CI: 0.88-2.73) higher in patients with long-term PPIs use compared with patients who did not use PPIs. Although the use of PPIs provides short-term health benefits, their prolonged use is associated with minor and also potentially major adverse health outcomes. Hence, we strongly recommend that the prescription of PPIs should be done with caution to improve the medication's efficacy and patients' safety.

AB - The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare professionals and patients about their potentially adverse effects. In July 2016, we searched through Medline (PubMed), Embase, and the Cochrane Library from inception using common keywords. We included observational studies that provided risk estimates on the long-term use of PPIs and their adverse effects. Overall, 43 studies were included in the systematic review, of which 28 studies were also included in the random effect meta-analysis. Odds of community-acquired pneumonia, hip fracture, and colorectal cancer were 67% [odds ratio (OR)=1.67; 95% confidence interval (CI): 1.04-2.67], 42% (OR=1.42; 95% CI: 1.33-1.53), and 55% (OR=1.55; 95% CI: 0.88-2.73) higher in patients with long-term PPIs use compared with patients who did not use PPIs. Although the use of PPIs provides short-term health benefits, their prolonged use is associated with minor and also potentially major adverse health outcomes. Hence, we strongly recommend that the prescription of PPIs should be done with caution to improve the medication's efficacy and patients' safety.

KW - Alzheimer

KW - cancer

KW - cardiac disease

KW - gastroesophageal reflux disease

KW - kidney disease

KW - proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85054716076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054716076&partnerID=8YFLogxK

U2 - 10.1097/MEG.0000000000001198

DO - 10.1097/MEG.0000000000001198

M3 - Review article

C2 - 30028775

VL - 30

SP - 1395

EP - 1405

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 12

ER -